Tetsuya Akiyama

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A

X. Rosa, Mercedes Prudencio, Yuka Koike et al. · Nature · 2022 · 575 citations · Full text

Life Sciences, Genetics, Neuroscience +17

Establishment of In Vitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells

Naoki Ichiyanagi, Koki Fujimori, Masato Yano et al. · Stem Cell Reports · 2016 · 104 citations · Full text

Life Sciences, Neurology, Neuroscience +17

Aberrant axon branching via Fos-B dysregulation in FUS-ALS motor neurons

Tetsuya Akiyama, Naoki Suzuki, Mitsuru Ishikawa et al. · EBioMedicine · 2019 · 82 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9